The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the FDA advanced an initiative to implement real-time clinical trials. Elsewhere, UCB made… Read More
News round-up for 4 – 8 May by Bruno Quinney, Content Team at DDW. This week, the FDA has advanced an initiative to implement real-time clinical trials. Elsewhere, UCB has made headlines for through an acquisition and its cancer research venture. The top stories: FDA moves… Read More
A previously undiscovered target for treating malaria could pave the way for a new generation of drugs, experts say. Researchers from the Universities of Bath and Leeds, UK have made a significant advance in the fight against malaria by uncovering a promising new potential target for drug discovery. … Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the UK made headlines for both the investment it has attracted and… Read More
News round-up for 27 April – 1 May by Bruno Quinney, Content Team at DDW. This week, the UK has made headlines for both the investment it has attracted and the clinical trial reforms it has rolled out. Elsewhere, the world’s first antimalarial drug for newborns could soon address a critical unmet… Read More
The world’s first and only malaria drug for newborns has been cleared globally, marking a crucial step towards addressing a long-standing gap in malaria care. Coartem (artemether-lumefantrine) Baby, developed by Medicines for Malaria Venture (MMV) and Novartis, has been prequalified by the World Health Organization (WHO) as the first… Read More
Pharmaceutical companies GSK and ViiV Healthcare have invested £6 million ($8 million) in the Global Fund to Fight AIDS, Tuberculosis and Malaria. The investment will strengthen community-led responses to HIV, tuberculosis (TB) and malaria in lower income countries. The commitment will also be matched by the Gates… Read More
The University of Oxford and ReciBioPharm, Recipharm’s Advanced Biologics division, are expanding their long-standing collaboration with the development of two blood-stage malaria vaccine candidates for Phase I/II clinical trials. Since 2016, the collaboration has delivered five vaccine candidates and will now actively progress the manufacture of R78C… Read More
A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new prevention methods, according to a study from researchers at the National Institutes of Health (NIH) published in Science. Of the five species of… Read More
In two separate studies, malaria researchers are exploring the potential of a long-acting injectable preventive compound and an approach from cancer treatments that could be used as a single-dose cure. Medicines for Malaria Venture (MMV) and Quotient Sciences have begun the first clinical trial for their… Read More
A single injection of an experimental monoclonal antibody called L9LS was 77% effective at preventing malaria infection in children in Mali, according to the results of a mid-stage clinical trial. L9LS binds to and neutralises ‘sporozoites’, the form of the malaria parasite transmitted by mosquitoes that… Read More
Anti-malarial drug artesunate-mefloquine has been proven to be effective against another devastating parasitic disease, thanks to research at the Institute of Tropical Medicine (ITM). Schistosomiasis affects over 200 million individuals around the world, predominantly in poor populations living in rural areas of sub-Saharan Africa. Read More
The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). Developed by The University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant technology, R21/Matrix-M malaria vaccine… Read More
Research published in Science shows that a naturally occurring bacterium discovered by GSK scientists – Delftia tsuruhatensis Tres Cantos 1 (TC1) – could be the basis for new anti-malarial interventions. Studies done in collaboration at the Johns Hopkins Malaria Research Institute show that the bacterium can… Read More
News round-up for 10-14 April by DDW Digital Content Editor Diana Spencer. The headlines getting our attention this week all represent significant breakthroughs in the treatment of various diseases and could make a huge difference to the lives of these patients. Perhaps most significantly,… Read More
The R21/Matrix-M malaria vaccine has received regulatory clearance for use in Ghana by the country’s Food and Drugs Authority, making it the first country to approve the vaccine. R21/Matrix-M was developed by the University of Oxford and manufactured and scaled up by the Serum Institute of… Read More
